Hypodensity of platelet serotonin uptake sites in posttraumatic stress disorder: associated clinical features.
We have previously reported that binding to blood platelets of paroxetine, a selective serotonin (5-HT) reuptake inhibitor which binds to 5-HT uptake sites, is decreased in patients with posttraumatic stress disorder (PTSD). Specifically, we found a lower number of platelet 3H-paroxetine binding sites (Bmax) and a lower dissociation constant (Kd) for 3H-paroxetine binding in combat veterans with PTSD compared to normal control subjects. In the current study we assessed the relationship of platelet 3H-paroxetine binding to clinical features in 41 Vietnam combat veterans with SCID-diagnosed PTSD. The results indicated that Bmax of platelet 3H-paroxetine binding was negatively correlated with both state and trait anxiety, as well as with depressive and overall PTSD symptoms. However, there was no evidence that platelet 3H-paroxetine binding differed as a function of comorbid psychiatric diagnoses including major depression, other anxiety disorders, and substance abuse in these patients.
Fichtner
C G
CG
Psychiatry Service, Veterans Affairs Medical Center, North Chicago, Illinois 60064, USA.
O'Connor
F L
FL
Yeoh
H C
HC
Arora
R C
RC
Crayton
J W
JW
D000328:Adult; D001007:Anxiety / Q000097:blood / Q000209:etiology; D001792:Blood Platelets / Q000378:metabolism*; D003130:Combat Disorders / Q000097:blood*; D003866:Depressive Disorder / Q000097:blood / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D017374:Paroxetine / Q000097:blood / Q000493:pharmacokinetics; D012701:Serotonin / Q000097:blood* / Q000493:pharmacokinetics; D014316:Tritium
D014316:Tritium; D012701:Serotonin; D017374:Paroxetine